Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting


You May Also Like

Cue Biopharma to Host Investor Business Update Call and Webcast

Update on progress of selective immune modulation platformCAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) ...